Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price target at $75.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight CG Oncology, Inc.’s promising therapeutic developments. The company’s lead product, cretostimogene grenadenorepvec (Creto), has demonstrated significant advantages over competing treatments, particularly in terms of durability and safety for high-risk non-muscle invasive bladder cancer (HR-NMIBC). Creto’s impressive complete response rates and its ability to maintain these responses over extended periods underscore its potential as a leading therapy in this space.
Moreover, Creto’s safety profile is exceptional, with no treatment-related Grade 3 adverse events reported, setting it apart as a commercially viable option. The therapy’s minimal adverse effects and the absence of serious adverse events support its broad adoption in urology practices. Additionally, the expansion into treating papillary-only disease further showcases Creto’s versatility and strengthens its market potential. These compelling clinical outcomes and safety features form the basis of Maldonado’s positive outlook and Buy rating for CG Oncology, Inc.
According to TipRanks, Y. Maldonado is an analyst with an average return of -7.5% and a 27.27% success rate. Y. Maldonado covers the Healthcare sector, focusing on stocks such as ImmunityBio, Corbus Pharmaceuticals, and Day One Biopharmaceuticals.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $82.00 price target.